NASDAQ · Medical - Instruments & Supplies

NVCR (NVCR) Stock

$16.39 +4.46% NASDAQ: NVCR Healthcare

Valuation

MetricValue
Price$16.39
Market Cap$1.91B
P/E Ratio-15.27
P/B Ratio5.91
P/S Ratio2.39
EPS (TTM)$-1.17
52-Week High$19.99
52-Week Low$9.82
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-49.96%
ROA-11.06%
ROCE-45.29%
Gross Margin-23.51%
Operating Margin-23.51%
Net Margin-25.66%
Debt/Equity0.71
Current Ratio2.90

Annual Financials (USD)

Metric20212022202320242025
Revenue$535.0M$538.0M$509.0M$605.0M$655.0M
Operating Profit$-44.0M$-90.0M$-233.0M$-170.0M$-154.0M
Net Profit$-58.0M$-93.0M$-207.0M$-169.0M$-136.0M
EPS$-0.56$-0.88$-1.95$-1.56$-1.22
Op Margin-8.3%-16.6%-45.7%-28.2%-23.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.1B$1.2B$1.1B$1.2B$804.0M
Total Liabilities$729.0M$750.0M$784.0M$881.0M$464.0M
Cash$210.0M$115.0M$241.0M$164.0M$103.0M
Borrowings$582.0M$584.0M$596.0M$683.0M$290.0M

Latest News

Exelixis (EXEL) Earnings Expected to Grow: Should You Buy? Zacks · Jul 20, 2026 NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks · Jul 16, 2026 NovoCure's Cancer Treatment Device Option Pax Gets European Approval Zacks · Jul 1, 2026 Novocure to Report Second Quarter 2026 Financial Results Business Wire · Jul 1, 2026 Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer Business Wire · Jun 30, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$83.0M$31.0M$-73.0M$-26.0M$-49.0M
Investing Cash Flow$-169.0M$-161.0M$157.0M$-183.0M$411.0M
Financing Cash Flow$21.0M$10.0M$11.0M$2.0M$0
Net Cash Flow$-37.0M$-94.0M$127.0M$-76.0M$-63.0M
Free Cash Flow$59.0M$9.0M$-100.0M$-69.0M$-76.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-79.47
EV / EBITDA—
FCF Yield-2.98%
Quick Ratio2.70
Interest Coverage—
Return 1Y40.75%
Return 3Y-54.71%
Return 5Y-91.48%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AZTA $29.88 +6.22% -15.22 $1.38B 0.00%
BLFS $32.15 +2.78% -96.00 $1.57B 0.00%
ESTA $92.80 +0.28% -38.58 $2.73B 0.00%
EVOEvotec SE $2.01 -6.07% -3.26 $713.93M 0.00%
KMTS $23.99 +5.08% -3.85 $1.41B 0.00%

About NVCR

NVCR stock trades at $16.39 with a market capitalization of $1.91B. The stock is valued at a price-to-earnings (P/E) ratio of -15.27, price-to-book of 5.91, price-to-sales of 2.39. Over the past 52 weeks the stock has ranged between $9.82 and $19.99, and currently trades 18.0% below its 52-week high.

On profitability, NVCR generates a return on equity (ROE) of -49.96%, return on capital employed of -45.29%, an operating margin of -23.51%, a net profit margin of -25.66%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides